minocycline and Dementia--Vascular

minocycline has been researched along with Dementia--Vascular* in 2 studies

Other Studies

2 other study(ies) available for minocycline and Dementia--Vascular

ArticleYear
Early treatment of minocycline alleviates white matter and cognitive impairments after chronic cerebral hypoperfusion.
    Scientific reports, 2015, Jul-15, Volume: 5

    Subcortical ischemic vascular dementia (SIVD) caused by chronic cerebral hypoperfusion develops with progressive white matter and cognitive impairments, yet no effective therapy is available. We investigated the temporal effects of minocycline on an experimental SIVD exerted by right unilateral common carotid arteries occlusion (rUCCAO). Minocycline treated at the early stage (day 0-3), but not the late stage after rUCCAO (day 4-32) alleviated the white matter and cognitive impairments, and promoted remyelination. The actions of minocycline may not involve the inhibition of microglia activation, based on the effects after the application of a microglial activation inhibitor, macrophage migration inhibitory factor, and co-treatment with lipopolysaccharides. Furthermore, minocycline treatment at the early stage promoted the proliferation of oligodendrocyte progenitor cells (OPCs) in subventricular zone, increased OPC number and alleviated apoptosis of mature oligodendrocytes in white matter. In vitro, minocycline promoted OPC proliferation and increased the percentage of OPCs in S and G2/M phases. We provided direct evidence that early treatment is critical for minocycline to alleviate white matter and cognitive impairments after chronic cerebral hypoperfusion, which may be due to its robust effects on OPC proliferation and mature oligodendrocyte loss. So, early therapeutic time window may be crucial for its application in SIVD.

    Topics: Animals; Carotid Artery Injuries; Cell Proliferation; Cells, Cultured; Cognition Disorders; Dementia, Vascular; Disease Models, Animal; G2 Phase; Intramolecular Oxidoreductases; Lipopolysaccharides; Macrophage Migration-Inhibitory Factors; Male; Maze Learning; Mice; Mice, Inbred C57BL; Microglia; Microscopy, Electron; Minocycline; Neuroprotective Agents; Oligodendroglia; Rats; Rats, Sprague-Dawley; S Phase; Stem Cells; White Matter

2015
Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion.
    Journal of neuroscience research, 2006, Feb-01, Volume: 83, Issue:2

    White matter lesions are thought to result from chronic cerebral ischemia and constitute a core pathology of subcortical vascular dementia. This rarefaction has been known to be associated with microglial activation. We investigated whether minocycline, a microglial inhibitor, attenuates the white matter damage induced by chronic cerebral hypoperfusion that is used as a model of vascular dementia. Male Wistar rats were subjected to bilateral, permanent occlusion of the common carotid arteries (BCCAO) to induce chronic cerebral hypoperfusion. Minocycline or saline was injected daily for 2 weeks after BCCAO. In the corpus callosum and the optic tract, white matter damage observed with Klüver-Barrera staining was significantly attenuated in the minocycline-treated group compared to saline-treated controls. In control rats, immunoreactivities of major basic protein (MBP), Ox-42 as a microglial marker, and matrix metalloproteinase (MMP)-2 were increased in the corpus callosum. Minocycline significantly reduced these changes. Co-expression of Ox-42 and MMP-2 was confirmed by double immunofluorescence histochemistry. Our results suggest that chronic treatment with minocycline could be protective against at least some ischemic white matter damage, and its mechanism may be related to suppressing microglial activation.

    Topics: Analysis of Variance; Animals; Brain Damage, Chronic; CD11b Antigen; Corpus Callosum; Dementia, Vascular; Diagnostic Imaging; Disease Models, Animal; Drug Administration Schedule; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Minocycline; Myelin Basic Protein; Rats; Rats, Wistar; Visual Pathways

2006